About Orexin receptor type 2
Orexin receptor type 2 (HCRTR2) is a protein
from Homo sapiens identified by UniProt accession
O43614, 444 residues long.
MolForge cross-references it against 0 known binders and
127 disease associations.
Target properties
| Protein name | Orexin receptor type 2 |
| UniProt accession | O43614 |
| Gene | HCRTR2 |
| Organism | Homo sapiens |
| Length | 444 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (127)
Diseases linked to this target (Open Targets).
- insomnia · score 0.59
- Sleep Disorder · score 0.51
- sleep duration · score 0.44
- blood urea nitrogen measurement · score 0.43
- circadian rhythm · score 0.42
- chronotype measurement · score 0.41
- post-traumatic stress disorder · score 0.40
- excessive daytime sleepiness measurement · score 0.39
- hemoglobin measurement · score 0.38
- hematocrit · score 0.38
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43614-F1 | alphafold | PREDICTED | 78.96 | — |
Amino-acid sequence (444 residues)
MSGTKLEDSP PCRNWSSASE LNETQEPFLN PTDYDDEEFL RYLWREYLHP KEYEWVLIAG YIIVFVVALI GNVLVCVAVW KNHHMRTVTN YFIVNLSLAD VLVTITCLPA TLVVDITETW FFGQSLCKVI PYLQTVSVSV SVLTLSCIAL DRWYAICHPL MFKSTAKRAR NSIVIIWIVS CIIMIPQAIV MECSTVFPGL ANKTTLFTVC DERWGGEIYP KMYHICFFLV TYMAPLCLMV LAYLQIFRKL WCRQIPGTSS VVQRKWKPLQ PVSQPRGPGQ PTKSRMSAVA AEIKQIRARR KTARMLMIVL LVFAICYLPI SILNVLKRVF GMFAHTEDRE TVYAWFTFSH WLVYANSAAN PIIYNFLSGK FREEFKAAFS CCCLGVHHRQ EDRLTRGRTS TESRKSLTTQ ISNFDNISKL SEQVVLTSIS TLPAANGAGP LQNW
Explore Orexin receptor type 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets